Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

789 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma.
Lorenc R, Shouval R, Flynn JR, Devlin SM, Saldia A, De Abia AL, De Lapuerta MC, Tomas AA, Cassanello G, Leslie LA, Rejeski K, Lin RJ, Scordo M, Shah GL, Palomba ML, Salles G, Park J, Giralt SA, Perales MA, Ip A, Dahi PB. Lorenc R, et al. Among authors: flynn jr. Transplant Cell Ther. 2024 Oct;30(10):990-1000. doi: 10.1016/j.jtct.2024.06.027. Epub 2024 Jul 6. Transplant Cell Ther. 2024. PMID: 38972512
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality.
Wudhikarn K, Pennisi M, Garcia-Recio M, Flynn JR, Afuye A, Silverberg ML, Maloy MA, Devlin SM, Batlevi CL, Shah GL, Scordo M, Palomba ML, Dahi PB, Sauter CS, Santomasso BD, Mead E, Perales MA. Wudhikarn K, et al. Among authors: flynn jr. Blood Adv. 2020 Jul 14;4(13):3024-3033. doi: 10.1182/bloodadvances.2020001972. Blood Adv. 2020. PMID: 32614964 Free PMC article.
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma.
Wudhikarn K, Palomba ML, Pennisi M, Garcia-Recio M, Flynn JR, Devlin SM, Afuye A, Silverberg ML, Maloy MA, Shah GL, Scordo M, Dahi PB, Sauter CS, Batlevi CL, Santomasso BD, Mead E, Seo SK, Perales MA. Wudhikarn K, et al. Among authors: flynn jr. Blood Cancer J. 2020 Aug 5;10(8):79. doi: 10.1038/s41408-020-00346-7. Blood Cancer J. 2020. PMID: 32759935 Free PMC article.
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.
Sermer D, Batlevi C, Palomba ML, Shah G, Lin RJ, Perales MA, Scordo M, Dahi P, Pennisi M, Afuye A, Silverberg ML, Ho C, Flynn J, Devlin S, Caron P, Hamilton A, Hamlin P, Horwitz S, Joffe E, Kumar A, Matasar M, Noy A, Owens C, Moskowitz A, Straus D, von Keudell G, Rodriguez-Rivera I, Falchi L, Zelenetz A, Yahalom J, Younes A, Sauter C. Sermer D, et al. Blood Adv. 2020 Oct 13;4(19):4669-4678. doi: 10.1182/bloodadvances.2020002118. Blood Adv. 2020. PMID: 33002134 Free PMC article.
Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Lin A, Flynn J, DeRespiris L, Figgins B, Griffin M, Lau C, Proli A, Devlin SM, Cho C, Tamari R, Jakubowski AA, Papadopoulos EB, Giralt SA, Perales MA, Seo SK, Shaffer B. Lin A, et al. Transplant Cell Ther. 2021 Jan;27(1):85.e1-85.e6. doi: 10.1016/j.bbmt.2020.10.009. Epub 2020 Oct 11. Transplant Cell Ther. 2021. PMID: 33053449 Free PMC article.
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Geyer MB, Ritchie EK, Rao AV, Vemuri S, Flynn J, Hsu M, Devlin SM, Roshal M, Gao Q, Shukla M, Salcedo JM, Maslak P, Tallman MS, Douer D, Park JH. Geyer MB, et al. Haematologica. 2021 Aug 1;106(8):2086-2094. doi: 10.3324/haematol.2020.251686. Haematologica. 2021. PMID: 33054114 Free PMC article.
The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy.
Garcia-Recio M, Wudhikarn K, Pennisi M, Alonso-Trillo R, Flynn J, Shouval R, Afuye AO, Silverberg ML, Batlevi CW, Dahi P, Devlin S, Giralt SA, Halton E, Ruiz J, Maloy M, Mead E, Palomba ML, Santomasso B, Sauter CS, Scordo M, Shah GL, Perales MA. Garcia-Recio M, et al. Transplant Cell Ther. 2021 Mar;27(3):233-240. doi: 10.1016/j.jtct.2020.10.022. Epub 2020 Dec 18. Transplant Cell Ther. 2021. PMID: 33781518 Free PMC article.
Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy.
Wudhikarn K, Flynn JR, Rivière I, Gönen M, Wang X, Senechal B, Curran KJ, Roshal M, Maslak PG, Geyer MB, Halton EF, Diamonte C, Davila ML, Sadelain M, Brentjens RJ, Park JH. Wudhikarn K, et al. Among authors: flynn jr. Blood. 2021 Aug 19;138(7):531-543. doi: 10.1182/blood.2020009515. Blood. 2021. PMID: 33851211 Free PMC article. Clinical Trial.
789 results